Infertility Female, Infertility (IVF Patients)
Conditions
Keywords
Receptiva, Depo Lupron Acetate, Norethindrone Acetate
Brief summary
This retrospective study aims to evaluate pregnancy outcomes in patients with a positive BCL6 test (ReceptivaDx, who were treated with either norethindrone acetate or Depo Lupron prior to embryo transfer. The current standard of care involves treatment with Depo Lupron, a GnRH agonist associated with significant hypoestrogenic side effects that mimic menopausal symptoms. Additionally, Depo Lupron is costly, with a retail price exceeding $2,000 per dose. In contrast, norethindrone acetate is a well-tolerated oral progestin, available at a fraction of the cost (under $100 for a one-month course). While prior studies have demonstrated comparable efficacy between Depo Lupron and norethindrone for managing endometriosis-associated pain, their relative effectiveness in improving reproductive outcomes-particularly in BCL6-positive patients undergoing embryo transfer-remains underexplored. This study seeks to address that gap by comparing ongoing pregnancy, live birth, and miscarriage rates between the two treatment groups. Hypothesis: IVF Patients testing positive for BCL6 and treated with norethindrone will not do worse than the current recommended treatment of 60 days Depo leuprolide as defined by two endpoint metrics, pregnancy rate and live birth rate.
Interventions
None listed
Sponsors
Inception Fertility Research Institute, LLC
Cicero Diagnostic
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* Diagnosis of recurrent pregnancy loss, recurrent implantation failure, unexplained infertility or severe dysmenorrhea and a positive BCL6 test Receptivadx * Underwent assisted reproductive technology (ART or IVF) * Treated with norethinedrone acetate 5 mg daily for 6 and 8 weeks or two monthly injections of Depo Leuprolide Acetate 7.5mg rior to embryo transfer cycle * Euploid embryo transfer cycle was initiated within 1 week of completion of suppression protocol * Adequate clinical documentation available, including treatment protocol, BCL6 results, and pregnancy outcomes * If Endometrial Receptivity Analysis (ERA) was performed, result must be "receptive" * A minimum uterine lining of 7.5mm was documented by ultrasound prior to the initiation of progesterone
Exclusion criteria
* Use of both norethinedrone acetate and Depo Leuprolide Acetate in the same treatment cycle * Incomplete ART or outcome data * Gestational carrier or egg donor * No prescribed adjuvant therapy (e.g., Lovenox, Neupogen, IVIG)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ongoing pregnancy rate | From beginning of treatment to 12 weeks post embryo transfer | To compare ongoing pregnancy rates in BCL6-positive patients treated with norethindrone acetate versus Depo Lupron acetate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Live birth rate | From start of treatment to 10 months post embryo transfer | To compare live birth rates in BCL6-positive patients treated with norethindrone acetate versus Depo Lupron acetate |
| Miscarriage Rate | From start of treatment to 20 weeks post embryo transfer | Defined as the loss of a clinically confirmed pregnancy before 20 weeks of gestation |
| Biochemical pregnancy rate | From start of treatment to 4 weeks post embryo transfer | Defined as a low positive serum HCG with an inappropriate rise, spontaneous resolution |
| Ectopic pregnancy rate | From start of treatment to 8 weeks post embryo transfer | — |
Countries
United States
Outcome results
None listed